Skip to main content
. Author manuscript; available in PMC: 2016 Sep 19.
Published in final edited form as: Curr Transplant Rep. 2014 Mar 13;1(2):78–85. doi: 10.1007/s40472-014-0012-y

Fig 1. Chronic AMR in the absence of acute AMR in eculizumab-treated patients.

Fig 1

At 3 months post transplant, no patients treated with eculizumab had transplant glomerulopathy (Banff cg score > 0), while this was present in 9.3&% of control patients. At 1 year, transplant glomerulopathy was present in 31.9% of control patients and 27.0% of eculizumab treated patients p=0.62.